Page last updated: 2024-11-05

isatoic anhydride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Isatoic anhydride is a versatile building block in organic synthesis, particularly for the preparation of pharmaceuticals and other bioactive compounds. It is a cyclic anhydride derived from anthranilic acid. The synthesis of isatoic anhydride typically involves the reaction of anthranilic acid with phosgene or a phosgene equivalent. Isatoic anhydride readily undergoes nucleophilic attack at the carbonyl group, leading to the formation of various derivatives. It serves as a precursor for the synthesis of many important heterocyclic compounds, including quinazolines, benzoxazoles, and phthalazines. Its reactivity and ability to form diverse derivatives have made it a valuable tool in drug discovery and development. Isatoic anhydride has been explored for its potential in the treatment of various diseases, including cancer, inflammation, and bacterial infections.'

isatoic anhydride: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8359
CHEMBL ID346059
SCHEMBL ID16251
MeSH IDM0114393

Synonyms (79)

Synonym
AC-3291
1h-[3,1]benzoxazine-2,4-dione
isatoic anhydride treated bsa
1h-benzo[d][1,3]oxazine-2,4-dione
nsc-29555
nsc29555
NCIOPEN2_002029
AE-641/30105041
brn 0136786
benzoic acid, 2-(carboxyamino)-, cyclic anhydride
hsdb 5017
nsc 104662
anthranilic acid, n-carboxy-, cyclic anhydride
n-carboxyanthranilic anhydride
ai3-24983
einecs 204-255-0
4h-3,1-benzoxazine-2,4(1h)-dione
isato acid anhydride
nsc-104662
2h-3,4(1h)-dione
anthranilic acid, cyclic anhydride
118-48-9
nsc104662
isatoic acid anhydride
isatoic anhydride
2h-3,1-benzoxazine-2,4(1h)-dione
isatoic acid,anhydride
inchi=1/c8h5no3/c10-7-5-3-1-2-4-6(5)9-8(11)12-7/h1-4h,(h,9,11
isatoic anhydride, 96%
NCGC00164009-01
CHEMBL346059 ,
1h-3,1-benzoxazine-2,4-dione
HMS1607F14
I0081
AKOS000120179
1h-3,1-benzoxazine-2,4-dione;isatoic anhydride
A803947
NCGC00164009-02
4-27-00-03330 (beilstein handbook reference)
unii-r8tfa74y4u
r8tfa74y4u ,
ec 204-255-0
STK711078
cas-118-48-9
tox21_303058
dtxcid906955
NCGC00257195-01
dtxsid6026955 ,
tox21_201325
NCGC00258877-01
BBL009904
BP-10896
FT-0627312
2,4-dihydro-1h-3,1-benzoxazine-2,4-dione
S12335
3,1-benzoxazine-2,4(1h)-dione
anthranilic acid n-carboxylic acid anhydride
CS-M0780
SCHEMBL16251
1,2-dihydro-3,1-benzoxazine-2,4-dione
2,4-dioxo-1,2-dihydro-4h-3,1-benzoxazine
isatoic acid anhydride [hsdb]
1h-benz(d)(1,3)oxazine-2,4-dione
FS-3311
1h-benzo[d][1,3]oxazine-2,4dione
2,4-dioxo-1h-3,1-benzoxazine
2h-3,1-benzoxazine-2,4-(1h)-dione
1h-benzo[d][1,3]oxazin-2,4-dione
2h-3,1-benzoxazine-2,4(1h)dione
3,1-benzoxazin-2,4-(1h)-dione
Q-103228
F0036-0953
mfcd00006700
isatoic anhydride, technical, >=94% (hplc)
bdbm50201570
DB11593
Q11286492
EN300-19149
Z104472968

Research Excerpts

Effects

ExcerptReferenceRelevance
"Isatoic anhydride (IA) has been shown to be a useful platform for quantifiable bioconjugation. "( Directly Quantifiable Biotinylation Using a Water-Soluble Isatoic Anhydride Platform.
Fessler, AB; Fowler, AJ; Ogle, CA, 2021
)
2.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency56.38130.007215.758889.3584AID1224835
AR proteinHomo sapiens (human)Potency69.63720.000221.22318,912.5098AID743042
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency76.95880.003041.611522,387.1992AID1159553
estrogen nuclear receptor alphaHomo sapiens (human)Potency62.63420.000229.305416,493.5996AID743075
aryl hydrocarbon receptorHomo sapiens (human)Potency34.90130.000723.06741,258.9301AID743085
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency21.68990.000323.4451159.6830AID743065
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Complement factor DHomo sapiens (human)IC50 (µMol)2.90002.90002.90002.9000AID1325986
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
proteolysisComplement factor DHomo sapiens (human)
complement activationComplement factor DHomo sapiens (human)
complement activation, alternative pathwayComplement factor DHomo sapiens (human)
response to bacteriumComplement factor DHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityComplement factor DHomo sapiens (human)
serine-type peptidase activityComplement factor DHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
extracellular regionComplement factor DHomo sapiens (human)
platelet alpha granule lumenComplement factor DHomo sapiens (human)
secretory granule lumenComplement factor DHomo sapiens (human)
extracellular exosomeComplement factor DHomo sapiens (human)
ficolin-1-rich granule lumenComplement factor DHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID22382Compound was tested for inhibition of chymotrypsin like serine protease for T1/2 for inactivation at the dose of 125 uM.1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Substituted isatoic anhydrides: selective inactivators of trypsin-like serine proteases.
AID22389Compound was tested for inhibition of trypsin like serine protease for T1/2 for inactivation at the dose of 125 uM.1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Substituted isatoic anhydrides: selective inactivators of trypsin-like serine proteases.
AID22372Compound was tested for T1/2 for inactivation of chymotrypsin like serine protease at the dose of 2.5 uM1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Substituted isatoic anhydrides: selective inactivators of trypsin-like serine proteases.
AID22384Compound was tested for inhibition of thrombin like serine protease for T1/2 for inactivation at the dose of 125 uM.1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Substituted isatoic anhydrides: selective inactivators of trypsin-like serine proteases.
AID22391Compound was tested for inhibition of trypsin like serine protease for T1/2 for inactivation at the dose of 2.5 uM; No inactivation within 1 hr1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Substituted isatoic anhydrides: selective inactivators of trypsin-like serine proteases.
AID22386Compound was tested for inhibition of thrombin like serine protease for T1/2 for inactivation at the dose of 2.5 uM; No inactivation within 1 hr1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Substituted isatoic anhydrides: selective inactivators of trypsin-like serine proteases.
AID22378Compound was tested for T1/2 for inactivation of plasmin like serine protease at the dose of 2.5 uM; No data1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Substituted isatoic anhydrides: selective inactivators of trypsin-like serine proteases.
AID22388Compound was tested for inhibition of thrombin like serine protease for T1/2 for inactivation at the dose of 25 uM; Complex inactivation kinetics was observed1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Substituted isatoic anhydrides: selective inactivators of trypsin-like serine proteases.
AID22392Compound was tested for inhibition of trypsin like serine protease for T1/2 for inactivation at the dose of 25 uM.1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Substituted isatoic anhydrides: selective inactivators of trypsin-like serine proteases.
AID22375Compound was tested for T1/2 for inactivation of chymotrypsin like serine protease at the dose of 25 uM1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Substituted isatoic anhydrides: selective inactivators of trypsin-like serine proteases.
AID1325986Binding affinity to complement factor D (unknown origin)2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Buried Hydrogen Bond Interactions Contribute to the High Potency of Complement Factor D Inhibitors.
AID22381Compound was tested for T1/2 for inactivation of plasmin like serine protease at the dose of 25 uM; No data1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
Substituted isatoic anhydrides: selective inactivators of trypsin-like serine proteases.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (6.06)18.7374
1990's6 (18.18)18.2507
2000's2 (6.06)29.6817
2010's18 (54.55)24.3611
2020's5 (15.15)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.89 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index5.29 (4.65)
Search Engine Demand Index63.62 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other34 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]